Skip to main content
Dermapharm Holding SE logo

Dermapharm Holding SE — Investor Relations & Filings

Ticker · DMP ISIN · DE000A2GS5D8 LEI · 5299009F0KNZINQQQK37 F Manufacturing
Open in API
Filings indexed 245 across all filing types
Latest filing 2024-05-22 Director's Dealing
Country DE Germany
Listing F DMP

About Dermapharm Holding SE

https://ir.dermapharm.de/index-EN.php

Dermapharm Holding SE is a manufacturer of branded pharmaceuticals and healthcare products, with a focus on the patent-free segment. The company operates an integrated business model that encompasses the entire value chain, including in-house research and development, production, and distribution. A dedicated pharmaceutical sales force manages the marketing and sales of its brand products. Dermapharm maintains a diversified portfolio concentrated on selected therapeutic areas, allowing it to establish strong market positions. The company operates several production, development, and distribution sites to support its operations and international expansion.

Recent filings

Filing Released Lang Actions
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details an acquisition of shares by an individual associated with the administrative body of Dermapharm Holding SE, including transaction dates, prices, and volumes. This directly corresponds to the definition of Director's Dealing.
2024-05-22 English
Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy
Earnings Release Classification · 100% confidence The document explicitly states it is publishing the 'results for the first three months of 2024' and uses keywords like 'Quarterly / Interim Statement/Quarter Results', 'Q1 2024', and provides detailed segment revenue and EBITDA figures for the first quarter. This content structure—a comprehensive financial review for a period shorter than a year—is characteristic of an Interim Report. Although it is presented as a news release via EQS, the core content is the financial report itself, not just an announcement of its publication (which would be RPA/RNS). Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q1 2024
2024-05-15 English
Q1 statement / Q1 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM STATEMENT Q1 2024' and contains comprehensive financial data, including a consolidated statement of financial position, a condensed statement of comprehensive income, and detailed segment performance analysis for the first quarter of 2024. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-15 English
Report Publication Announcement 2024
Report Publication Announcement Classification · 100% confidence The document is titled 'Preliminary announcement of the publication of quarterly reports and quarterly/interim statements' and explicitly states that the company 'hereby announces that the following financial reports shall be disclosed' on a future date (May 15, 2024). This structure—an announcement about the future release of a report, rather than the report itself—fits the definition of a Report Publication Announcement (RPA). The document is very short (1833 chars), reinforcing the 'MENU VS MEAL' rule, which suggests classifying it as an announcement (RPA) rather than the Interim Report (IR) itself.
2024-05-08 English
Dermapharm Holding SE: Wilhelm Beier, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the acquisition of shares by Wilhelm Beier, a Member of the administrative or supervisory body, including transaction dates, prices, and volumes. This content directly matches the definition for Director's Dealing (DIRS). The document length is short (2175 chars), but since it is the primary disclosure document itself, not an announcement *about* a report, DIRS is the correct classification over RPA or RNS.
2024-04-10 English
Dermapharm Holding SE: Anja Schorn, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Anja Schorn), their position, and the nature, price, and volume of a transaction involving company shares. This directly corresponds to the definition of Director's Dealing (DIRS). The document length is short, but the content is the primary disclosure itself, not an announcement of a separate report.
2024-03-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.